In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spark Therapeutics Inc.

www.sparktx.com

Latest From Spark Therapeutics Inc.

UniQure Aiming To Be First With Hemophilia B Gene Therapy

The company has come a long way since gene therapy flop Glybera, and claims best-in-class status for viral vector.

Research & Development Blood & Coagulation Disorders

Taking Aim At Advanced Therapies

Dmitry Kuzmin, managing partner, and Owen Smith, investment director, talk to In Vivo about 4BIO’s approach to venture investing in the biopharma sector: successes, red flags and targets for its second fund.

VC Playbook Business Strategies

FTC Vote On BMS-Celgene Acquisition Splits Over Drug Pricing

Divesting Celgene's psoriasis drug Otezla will remedy anticompetitive harm from acquisition, US Federal Trade Commission votes 3-2. Dissenting Democrat commissioners want broader review of pharma mergers.

M & A Enforcement

Gene And Cell Therapies In Asia: Can China Deliver Despite Murky Regulations?

The first country ever to approve a gene therapy, China has been lagging in the area since due to a lack of clear regulatory pathways and insufficient financial incentives. Now a new crop of developers are aiming to revitalize ambitions and make the country a major power for promising novel treatments for rare neurodegenerative conditions, retinal dystrophy, HIV and cancer.

China Gene Therapy
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Hepatic (Liver)
  • Metabolic Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Spark Therapeutics LLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Spark Therapeutics Inc.
  • Senior Management
  • Jeffrey D Marrazzo, CEO
    Stephen Webster, CFO
    Katherine A High, MD, Pres. & Head, R&D
    Daniel R Faga, CBO
    Frederico Mingozzi, PhD, CSO
  • Contact Info
  • Spark Therapeutics Inc.
    Phone: (215) 220-9300
    3737 Market St.
    Philadelphia, PA 19104
    USA
UsernamePublicRestriction

Register